Events
Steinberg-Dietrich Hall, Room 1201, 3620 Locust Walk, Philadelphia, PA
HP X LDI X CHIBE Research Seminar: John Cawley, PhD
Learn More
2026-10-13 12:00:00
2026-10-13 13:00:00
America/New_York
HP X LDI X CHIBE Research Seminar: John Cawley, PhD
Please note: Registration is required. In-person attendance is strongly encouraged, although virtual access will be provided for all registrants.
Co-sponsored with the Leanord Davis Institute of Health Economics.
John Cawley, PhD, is the Daniel Patrick Moynihan Chair in Public Policy and Professor of Economics and Public Administration and International Affairs at Syracuse University. He also serves as Senior Research Associate in the Maxwell-based Center for Policy Research and as a research affiliate in the Lerner Center for Public Health Promotion and Population Health. His research focuses on the economics of risky health behaviors; in particular, those that relate to obesity. He also serves as an Honorary Professor of Economics at the J.E. Cairnes School of Business and Economics at the University of Galway in Ireland. In 2016, he was named a Fulbright Specialist in Economics to Ireland through the Fulbright Scholar Program. Cawley is President-elect of the American Society of Health Economists and will serve as President from 2026-27. Since 2022 he has served on the board of directors of the International Health Economics Association. Cawley received a PhD in economics from the University of Chicago.
Steinberg-Dietrich Hall, Room 1201, 3620 Locust Walk, Philadelphia, PA
Penn Medical Ethics
3600 Civic Center Blvd., 8-031 (hybrid)
Penn Bioethics Seminar (PBS): "Trust, But Verify: How AI is Changing Radiology Practice" - Tessa Cook, MD, PhD
Learn More
2026-10-20 12:00:00
2026-10-20 13:00:00
America/New_York
Penn Bioethics Seminar (PBS): "Trust, But Verify: How AI is Changing Radiology Practice" - Tessa Cook, MD, PhD
Trust But Verify: How AI is Changing Radiology Practice
Tessa Cook, MD, PhD
Associate Professor of Radiology
Vice Chair of Practice Transformation
Hospital of the University of Pennsylvania
AI in healthcare is spreading rapidly, and radiology as a specialty is no stranger to this technology. More than 75% of FDA-authorized software-as-a-medical-device tools in healthcare are for radiology, and 90% of radiologists in a recent ACR survey reported using some form of AI in their practice.
Aside from the myriad questions about how and whether to deploy AI in the clinic and how to maximize the return on investment in both financial and non-financial terms, several ethical questions arise. In this talk, we’ll consider two: 1) do patients have a right to know when AI is used in the course of their care, and 2) what are the ethical and medicolegal considerations at play when a radiologist’s expert judgment disagrees with an AI result?
3600 Civic Center Blvd., 8-031 (hybrid)
Penn Medical Ethics
CCB 08-031, 8th Floor, 3600 Civic Center Blvd. (Note: Virtual attendees can join by accessing this link: https://upenn.zoom.us/j/95740259034.)
Health Policy Research Seminar: Daniel Ollendorf, PhD, MPH
Learn More
2026-10-22 10:00:00
2026-10-22 11:00:00
America/New_York
Health Policy Research Seminar: Daniel Ollendorf, PhD, MPH
Topic: "At the Intersection of Access and Affordability: A Brief, Tortured History of Health Technology Assessment and the Current Role of ICER.”
Co-sponsored with the Leanord Davis Institute of Health Economics and the Center for Technology, Innovation & Competition
Dr. Ollendorf will describe the evolution of health technology assessment as a discipline, its interaction with US health policy, and the current role of the Institute for Clinical and Economic Review as a private-sector research organization trying to bring relevant conversations on access, pricing, and ethics back into the mainstream.
Dan Ollendorf is ICER’s Chief Scientific Officer and Director of Health Technology Assessment (HTA) Methods and Engagement, with responsibility for managing the organization’s internal health economics capacity and program of external collaboration, as well as collaboration with international HTA bodies and other stakeholders on key process and methods topics.
From 2007-2018, Dr. Ollendorf was Chief Scientific Officer for ICER, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators. From 2018-2023, Dr. Ollendorf served as the Director of Value Measurement & Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, where he focused on value assessment methods, drug pricing policy, and building international capacity for and interest in HTA. In addition to his current role at ICER, Dr. Ollendorf maintains a faculty appointment at CEVR and continues to teach in the Center’s graduate certificate program as well as participate in ongoing research.
Dr. Ollendorf is also a non-resident Fellow in Global Health at the Center for Global Development and serves on the Board of Directors for the ISPOR, the Professional Society for Health Economics and Outcomes Research. From 2019-2024, he served as Chair of the Health Technology Assessment International (HTAi) Global Policy Forum. Dr. Ollendorf received his PhD in Clinical Epidemiology from the University of Amsterdam, and an MPH in Health Policy & Management/Epidemiology from Boston University.
CCB 08-031, 8th Floor, 3600 Civic Center Blvd. (Note: Virtual attendees can join by accessing this link: https://upenn.zoom.us/j/95740259034.)
Penn Medical Ethics
Silverman 240B, Penn Carey Law School, 3501 Sansom Street, Philadelphia, PA
The Unfinished Business of Reforming the FDA’s Accelerated Approval Pathway
Learn More
2026-10-22 16:30:00
2026-10-22 18:00:00
America/New_York
The Unfinished Business of Reforming the FDA’s Accelerated Approval Pathway
A Conversation with Stacie Dusetzina, PhD, Holly Fernandez Lynch, JD, MBE, and Dan Ollendorf, PhD, MPH.
Co-sponsored by the Center for Technology, Innovation & Competition and the Leonard Davis Institute of Health Economics
Register here.
The FDA’s accelerated approval pathway allows the agency to approve drugs for serious diseases with unmet treatment need based on predicted clinical benefit, which must be confirmed through postmarket studies. Accelerated approval’s tradeoffs between speed and certainty have received substantial attention, especially challenges associated with the rigor and completion of confirmatory studies. In the wake of the FDA’s controversial accelerated approval of a drug for Alzheimer’s disease, in 2021, Congress enacted several reforms, while the FDA offered additional guidance on the pathway and several reforms of its own. Where does accelerated approval stand today and what reforms are still needed? In this panel discussion, experts in medicine, economics, law, and ethics will discuss access, quality, cost, and other issues facing accelerated approval.
Silverman 240B, Penn Carey Law School, 3501 Sansom Street, Philadelphia, PA
Penn Medical Ethics
3600 Civic Center Blvd., 8-031 (hybrid)
Penn Bioethics Seminar (PBS): "Setting Priorities in Allocating Scarce Health Resources" - Ole F. Norheim, MD
Learn More
2026-10-27 12:00:00
2026-10-27 13:00:00
America/New_York
Penn Bioethics Seminar (PBS): "Setting Priorities in Allocating Scarce Health Resources" - Ole F. Norheim, MD
Setting Priorities in Allocating Scarce Health Resources
Ole F. Norheim, MD
Mary B. Saltonstall Professor of Ethics and Population Health
Global Health and Population, Harvard T.H. Chan School of Public Health
Health systems everywhere face the same hard question: how should limited resources be allocated when needs exceed budgets? In this talk, Professor Ole F. Norheim examines the ethical foundations of priority setting in health care and the practical tools available to decision makers. Drawing on decades of work in global health and in Norway, he explores how evidence and economic analysis can inform efficient, fair and transparent priority setting.
Norheim argues that efficiency alone is insufficient. Ethical principles, including giving priority to the worse off and reducing unjust health inequalities, must be embedded in policy frameworks. He discusses how severity of illness, lifetime health prospects, and distributive justice can be operationalized alongside cost-effectiveness thresholds to guide real-world decisions.
Streaming available via Zoom.
3600 Civic Center Blvd., 8-031 (hybrid)
Penn Medical Ethics
To be added to MEHP's events listserv, please contact lisa.bailey@pennmedicine.upenn.edu.